ANIK

14.89

0.07% 0.010

Handel nachbörslich: 14.89

Anika Therapeutics Inc (ANIK)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.88

Offen:

$14.94

24-Stunden-Volumen:

56,074

Relative Volume:

0.44

Marktkapitalisierung:

$198.12M

Einnahmen:

$116.26M

Nettoeinkommen (Verlust:

$-11.08M

KGV:

-18.81

EPS:

-0.7917

Netto-Cashflow:

$1.04M

1W Leistung:

+0.47%

1M Leistung:

-3.12%

6M Leistung:

+52.25%

1J Leistung:

+32.47%

1-Tages-Spanne:

$14.57

$15.03

1-Wochen-Bereich:

$14.57

$15.21

52-Wochen-Spanne:

$7.8701

$16.24

Anika Therapeutics Inc Stock (ANIK) Company Profile

Firmenname

Anika Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Drug Manufacturers - Specialty & Generic (86)

Telefon

(781) 457-9000

Adresse

32 WIGGINS AVENUE, BEDFORD, MA

Mitarbeiter

235

Twitter

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

ANIK's Discussions on Twitter

Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANIK Anika Therapeutics Inc	14.89	197.99M	116.26M	-11.08M	1.04M	-0.7917
TAK Takeda Pharmaceutical Co Adr	15.87	51.34B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.24	41.15B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.61	39.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	80.23	34.09B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	578.43	24.13B	3.17B	1.29B	1.01B	27.09

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-17	Eingeleitet	B. Riley Securities	Buy
2024-11-01	Bestätigt	Barrington Research	Outperform
2023-08-14	Hochstufung	Barrington Research	Mkt Perform → Outperform
2023-03-07	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-11-09	Hochstufung	Barrington Research	Mkt Perform → Outperform
2022-10-14	Fortgesetzt	Stephens	Equal-Weight
2022-03-09	Herabstufung	Barrington Research	Outperform → Mkt Perform
2022-03-09	Herabstufung	Stephens	Overweight → Equal-Weight
2021-11-16	Eingeleitet	Stephens	Overweight
2021-07-16	Eingeleitet	UBS	Neutral
2020-12-16	Hochstufung	Barrington Research	Mkt Perform → Outperform
2020-05-08	Herabstufung	Barrington Research	Outperform → Mkt Perform
2020-01-21	Hochstufung	Sidoti	Neutral → Buy
2020-01-10	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2019-11-05	Eingeleitet	BWS Financial	Sell
2019-09-24	Bestätigt	Barrington Research	Outperform
2019-09-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-07-25	Hochstufung	First Analysis Sec	Neutral → Strong Buy
2019-02-22	Herabstufung	First Analysis Sec	Outperform → Neutral
2019-02-22	Herabstufung	Sidoti	Buy → Neutral
2018-07-27	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-06-20	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-06-20	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2018-05-04	Hochstufung	Barrington Research	Mkt Perform → Outperform
2018-02-23	Herabstufung	Barrington Research	Outperform → Mkt Perform
2018-01-24	Hochstufung	First Analysis Sec	Equal-Weight → Overweight
2017-10-27	Bestätigt	Barrington Research	Outperform
2016-05-09	Hochstufung	Singular Research	BUY - Long-Term → Buy
2016-04-27	Herabstufung	Northland Capital	Outperform → Market Perform
2016-02-26	Bestätigt	Barrington Research	Outperform

Alle ansehen

Anika Therapeutics Inc Aktie (ANIK) Neueste Nachrichten

04:41 AM

ANIK Stock Analysis: Anika Therapeutics Inc. gains 3.31 percent daily, trades at 14.98 dollar - Newser

04:41 AM

May 22, 2026

Trading Systems Reacting to (ANIK) Volatility - Stock Traders Daily

May 22, 2026

May 21, 2026

ANIK Q1 2026 Earnings: Surprise Profit Swing as Anika Therapeutics Beats ExpectationsAnnual Earnings Summary - Newser

May 21, 2026

Why Is Anika Therapeutics, Inc. (ANIK) Stock Up Today? - Meyka

May 21, 2026

May 20, 2026

Anika Therapeutics Signals Momentum Amid Regulatory Risks - The Globe and Mail

May 20, 2026

Anika Therapeutics honors Clinical Trials Day as it advances patient outcomes - Traders Union

May 20, 2026

Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN

May 20, 2026

May 19, 2026

Why Is Anika Therapeutics, Inc. (ANIK) Stock Down Today? - Meyka

May 19, 2026

May 18, 2026

Anika Therapeutics invites ESSKA Congress delegates to explore advances in HA-based cartilage repair - Traders Union

May 18, 2026

May 15, 2026

About Us | Oil & Gas JournalAnika Therapeutics Inc.Common Stock (Nasdaq:ANIK) Stock Quote - FinancialContent

May 15, 2026

May 14, 2026

TradingKey - TradingKey

May 14, 2026

May 11, 2026

How Anika Therapeutics Inc. (ANIK) Affects Rotational Strategy Timing - Stock Traders Daily

May 11, 2026

May 09, 2026

Anika Therapeutics (ANIK) Eps Diluted (TTM) - Zacks Investment Research

May 09, 2026

May 08, 2026

How Anika (ANIK) margins compare to industry leaders (+0.13%) 2026-05-08High Attention Stocks - newser.com

May 08, 2026

May 07, 2026

Anika Therapeutics explores why skin heals rapidly but tendons and cartilage lag in recovery - Traders Union

May 07, 2026

May 06, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada

May 04, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com

May 04, 2026

Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan

May 04, 2026

May 03, 2026

President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance

May 03, 2026

May 02, 2026

Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart

May 01, 2026

ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative

May 01, 2026

Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co

May 01, 2026

Apr 30, 2026

Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus

Apr 30, 2026

Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com Australia

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com

Apr 30, 2026

Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative

Apr 30, 2026

Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan

Apr 30, 2026

Anika Therapeutics : 2026 Proxy Statement - marketscreener.com

Apr 30, 2026

Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha

Apr 30, 2026

Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Apr 30, 2026

Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union

Apr 30, 2026

(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 30, 2026

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan

Apr 30, 2026